Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Southern Copper Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Southern Copper Corp trades at $199.2 (market cap $175.13B). The key difference: Southern Copper Corp is far larger — about 61.2× Dyne Therapeutics Inc. Common Stock's market cap, and Southern Copper Corp pays a 2.12% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Southern Copper Corp for 62 Days on average.
| DYN | SCCO | |
|---|---|---|
Market Cap | $2.86B | $175.13B |
Volume | 3,341,579 | 611,484 |
Sector | Health | Basic Materials |
52-Week High | $26.78 | $219.70 |
52-Week Low | $14.60 | $120.02 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $2.18B | $176.43B |
Dividend Yield | — | 2.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Southern Copper (SCCO) trades at $200.68, down 3.84% on the day, but maintains strong fundamentals with impressive earnings beats and robust profitability metrics. The company shows consistent revenue growth from $10.0B in 2022 to $13.4B in 2025, with net income margins expanding to 35.87%. Technical indicators show a bullish trend with support at $204 and resistance at $210, while analyst sentiment remains divided with a consensus price target of $165.60.
SCCO presents a mixed investment case with exceptional profitability and growth prospects from its Mexican projects, but faces valuation concerns with a P/E of 31.12 and divided analyst ratings. Key risks include copper price volatility and execution challenges, while institutional interest remains active with recent purchases by Virginia Retirement Systems.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
